Milestone Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIST research report →
Companywww.milestonepharma.com
Milestone Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
- CEO
- Joseph G. Oliveto
- IPO
- 2019
- Employees
- 33
- HQ
- Montreal, QC, CA
Price Chart
Valuation
- Market Cap
- $128.83M
- P/E
- -2.86
- P/S
- 72.22
- P/B
- 5.42
- EV/EBITDA
- -3.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.67%
- Op Margin
- -3669.39%
- Net Margin
- -3832.01%
- ROE
- -339.38%
- ROIC
- -37.64%
Growth & Income
- Revenue
- $1.55M · 0.00%
- Net Income
- $-63,058,000 · -51.88%
- EPS
- $-0.75 · -11.94%
- Op Income
- $-62,485,000
- FCF YoY
- -70.85%
Performance & Tape
- 52W High
- $3.06
- 52W Low
- $1.00
- 50D MA
- $1.71
- 200D MA
- $1.90
- Beta
- 1.04
- Avg Volume
- 2.05M
Get TickerSpark's AI analysis on MIST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Oliveto Joseph | sell | 36,500 |
| Mar 17, 26 | Sandoval David I. | other | 400,000 |
| Feb 2, 26 | Oliveto Joseph | other | 679,000 |
| Feb 2, 26 | Bharucha David | other | 204,000 |
| Feb 2, 26 | Nelson Jeffrey Edward | other | 204,000 |
| Feb 2, 26 | Muller Lorenz | other | 204,000 |
| Feb 2, 26 | Hasija Amit | other | 204,000 |
| Feb 2, 26 | Muller Lorenz | other | 204,000 |
| Feb 2, 26 | Muller Lorenz | other | 136,000 |
| Feb 2, 26 | Hasija Amit | other | 204,000 |
Our MIST Coverage
We haven't published any research on MIST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MIST Report →